CRP and rheumatoid arthritis: With tocilizumab, a humanized mouse immunoglobulin G1 monoclonal antibody against the IL-6R, a higher rate of DAS28-ESR remission and improvement of swollen and tender joint counts after both 24 and 52 weeks was reported among Japanese patients with RA whose CRP levels normalized within 12 weeks of starting treatment compared with those whose levels did not normalize [11].